Current studies into retatrutide, a dual stimulant for GLP-1 and GIP receptors, are showing significant effects in managing obesity and diabetes 2 disease. Preclinical evidence suggest a unique mechanism contributing https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/